Amarin Corporation plc (NASDAQ: AMRN) announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE